ReVision Therapeutics, Inc. — Form D
ReVision Therapeutics, Inc. of La Jolla, CA, a company, filed a Form D exempt-offering notice with the SEC on 2010-04-23. The offering totals $5.0M, of which $2.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2010-04-23
- Form: D
- Accession: 0001489829-10-000001
- Industry: Biotechnology
- Exemptions: 06
- Total offering: $5.0M
- Amount sold: $2.3M
- Remaining: $2.7M
- Investors: 11
- Date of first sale: 2010-04-08
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-141014
Issuer
- Name: ReVision Therapeutics, Inc.
- CIK: 0001489829
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2010
- Address: 11099 North Torrey Pines Road, Suite 290, La Jolla, CA, 92037
- Phone: 858.348.2180
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Jay Lichter, Ph.D. | Director | La Jolla, CA |
| Jay Lichter, Ph.D. | Executive Officer | La Jolla, CA |
| David Weber | Director | New York, NY |
| Douglas Downs | Executive Officer | La Jolla, CA |
| Kevin Kinsella | Director | Beverly, MA |
| Nathan Mata | Executive Officer | La Jolla, CA |
Other filings by this issuer (2)
More